Expert Perspectives & Insights into the Evolving Treatment of Refractory Metastatic Colorectal Cancer
Episodes
Specialty:
All
All AI for Oncology Biosimilars Brain Cancer Breast Cancer CAR T-Cell Therapy Disparities in Cancer Care Gastrointestinal Cancer Genitourinary Cancers Global Oncology Graft-vs-Host Disease Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive Care
EP. 1: Overview of Current mCRC Treatment Landscape By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.
EP. 2: Evaluating 3L Treatment Landscape Evolution By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Dr Parikh drives a conversation surrounding 3L treatment for patients diagnosed with metastatic colorectal cancer.
EP. 3: Fruquintinib MoA and Toxicity Profile Overview By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Key safety considerations for the use of fruquintinib are explored.
EP. 4: Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.
EP. 5: FRESCO-2 Study Highlights By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Medical experts provide key takeaways and impacts from the FRESCO-2 study.
EP. 6: Dose Modifications and Tolerability Associated with mCRC Treatment Regimens By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.
EP. 7: Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.
EP. 8: Consideration for Fruquintinib Dosing and Titration By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Mark A Lewis, MD, and Scott Paulson, MD, share their experiences utilizing fruquintinib.
EP. 9: Fatigue Associated with Bevacizumab, Fruquintinib, TAS-102 Therapies By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Side effect profiles driven by fruquintinib use are discussed.
EP. 10: Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.
EP. 11: Considerations for Platinum-based Therapy By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.
EP. 12: Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.
EP. 13: Real-World Data Surrounding Sequencing Strategies for Refractory mCRC By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD, Scott Paulson, MD Multiple abstracts from ESMO 2023, including a focus on tumor location, are highlighted.
EP. 14: Data Surrounding Treatment for MSI-high Patients from ASCO 2024 By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.
EP. 15: Unmet Needs Surrounding mCRC Treatment By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Key opportunities to improve the mCRC treatment landscape are illustrated by the expert panelists.
EP. 16: Anticipating Key Studies and Pipeline Treatments in mCRC Landscape By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.
